However, in a recent randomized, double‐blind, phase 2 clinical trial, the use of humanized TGF‐β1 monoclonal antibody (TGF‐β1 mAb) fails to show its therapeutic effect on patients with DKD.13 The gene discussed is TGFB1; the disease is diabetic kidney disease.